Andrew C. Stone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew C. Stone has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Kathleen Dungan
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, USA
2 shared publicationsB Wang
Chinese Academy of Medical Sciences, Nanjing, China
1 shared publication- Bethany Young Holt
1 CAMI Health, Initiative for MPTs, Public Health Institute, Oakland, CA, United States
1 shared publication C Deal
NIH/DMID, Washington, DC, United States
1 shared publicationJ Manning
USAID, Washington, DC, United States
1 shared publication- Joe Romano
NWJ Group, LLC., Wayne, Pennsylvania, USA
1 shared publication
Latest Publications
- 8 July 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis
Background: Insulin is commonly used to manage steroid-induced hyperglycemia. However, optimal dosing strategies for long-acting steroids like dexamethasone remain unclear. Objectives: This study evaluated insulin glargine use for dexamethasone-induced hyperglycemia (DIH) and evaluated factors associated with achieving glucose targets (AGTs). Methods: This retrospective, single-centered cohort study included adult, noncritically ill patients who received once-daily insulin glargine and dexamethasone for at least 3 consecutive days during admissions between July 1, 2021, and July 31, 2023. Patients were excluded if they had type 1 diabetes mellitus or received intravenous insulin within the first 3 days. The primary outcome was the percentage of patients AGT, defined as mean blood glucose 70 to 180 mg/dL on day 3 of combination therapy. Patients were then stratified into AGT and persistent hyperglycemia (PH) cohorts to evaluate secondary outcomes which included hypoglycemia incidence and patient or treatment characteristics associated with AGT. Results: Among 118 patients included, 28 (24%) were in the AGT cohort and 90 (76%) were in the PH cohort. The AGT cohort had a lower mean body mass index (29.1 vs 33.7 kg/m 2 , P = .02) and fewer patients with preexisting type 2 diabetes mellitus (85.7% vs 97.8%, P = .03). Median insulin glargine units standardized by dexamethasone dose was similar between cohorts (2.25 [1.08-3.33] vs 2.00 [1.17-4.00] units/mg/day, P = .98). The PH cohort required significantly higher median daily bolus insulin doses (24 vs 6 units/day, P < .01). There was 1 patient, who was in the AGT cohort, who experienced hypoglycemia. Conclusion and Relevance: This study suggests that current practice underdoses insulin glargine initially for DIH management and relies on reactive bolus insulin with limited success. Earlier and more assertive insulin glargine dosing is warranted to improve early glycemic control without substantially increasing hypoglycemia risk. Limitations include the retrospective single-centered study design and limited sample size with imbalanced cohorts.
- 8 July 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis
Background: Insulin is commonly used to manage steroid-induced hyperglycemia. However, optimal dosing strategies for long-acting steroids like dexamethasone remain unclear. Objectives: This study evaluated insulin glargine use for dexamethasone-induced hyperglycemia (DIH) and evaluated factors associated with achieving glucose targets (AGTs). Methods: This retrospective, single-centered cohort study included adult, noncritically ill patients who received once-daily insulin glargine and dexamethasone for at least 3 consecutive days during admissions between July 1, 2021, and July 31, 2023. Patients were excluded if they had type 1 diabetes mellitus or received intravenous insulin within the first 3 days. The primary outcome was the percentage of patients AGT, defined as mean blood glucose 70 to 180 mg/dL on day 3 of combination therapy. Patients were then stratified into AGT and persistent hyperglycemia (PH) cohorts to evaluate secondary outcomes which included hypoglycemia incidence and patient or treatment characteristics associated with AGT. Results: Among 118 patients included, 28 (24%) were in the AGT cohort and 90 (76%) were in the PH cohort. The AGT cohort had a lower mean body mass index (29.1 vs 33.7 kg/m 2 , P = .02) and fewer patients with preexisting type 2 diabetes mellitus (85.7% vs 97.8%, P = .03). Median insulin glargine units standardized by dexamethasone dose was similar between cohorts (2.25 [1.08-3.33] vs 2.00 [1.17-4.00] units/mg/day, P = .98). The PH cohort required significantly higher median daily bolus insulin doses (24 vs 6 units/day, P < .01). There was 1 patient, who was in the AGT cohort, who experienced hypoglycemia. Conclusion and Relevance: This study suggests that current practice underdoses insulin glargine initially for DIH management and relies on reactive bolus insulin with limited success. Earlier and more assertive insulin glargine dosing is warranted to improve early glycemic control without substantially increasing hypoglycemia risk. Limitations include the retrospective single-centered study design and limited sample size with imbalanced cohorts.
- 22 August 2021
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (10) , 804-810
Insulin NPH for steroid‐induced hyperglycemia: Predictors for success
Study Objective: This study aimed to evaluate the efficacy of insulin neutral protamine Hagedorn (NPH) for steroid‐induced hyperglycemia and identify factors associated with achievement of euglycemia. Design: Retrospective, single center, cohort analysis. Setting: Quaternary care academic medical center. Patients: Adult patients with steroid‐induced hyperglycemia on combination therapy of an intermediate‐acting steroid and once daily NPH. Intervention: The primary outcome was the percentage of patients who achieved euglycemia on day 3 of combination therapy. Patients were divided into euglycemic and dysglycemic cohorts based on the primary outcome. Univariate analysis on baseline characteristics, NPH dose, and steroid dose based on prednisone equivalent dose (PED) was conducted to identify differences between the cohorts. Safety analysis was conducted to detect differences between the two cohorts. Measurements and Main Results: Of 142 patients included in the primary analysis, 50 (35.2%) achieved euglycemia on day 3 of combination therapy. In univariate analysis, patients who achieved euglycemia had significantly higher median NPH dose standardized to steroid dose on day 1 (0.5 units/mg PED [25%–75% interquartile range (IQR) 0.4–0.8] vs 0.4 units/mg PED [0.2–0.8]; p = 0.046), lower median blood glucose prior to combination therapy on day 3 (111 mg/dl [96–160] vs 136 mg/dl [113–198]; p = 0.008), and lower median blood glucose 4 hours after administration of combination therapy on day 3 (147 mg/dl [116–197] vs 190 mg/dl [153–245]; p = 0.003) compared to patients who did not achieve euglycemia, respectively. Hypoglycemia and life‐threatening hypoglycemia occurred at similar rates between the two cohorts. Conclusions: Neutral protamine Hagedorn is a safe and efficacious option for acute care hospitalized patients experiencing steroid‐induced hyperglycemia. More aggressive dosing initiation of NPH based on steroid dose may allow for earlier achievement of euglycemia without a difference in hypoglycemia.
- 22 August 2021
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (10) , 804-810
Insulin NPH for steroid‐induced hyperglycemia: Predictors for success
Study Objective: This study aimed to evaluate the efficacy of insulin neutral protamine Hagedorn (NPH) for steroid‐induced hyperglycemia and identify factors associated with achievement of euglycemia. Design: Retrospective, single center, cohort analysis. Setting: Quaternary care academic medical center. Patients: Adult patients with steroid‐induced hyperglycemia on combination therapy of an intermediate‐acting steroid and once daily NPH. Intervention: The primary outcome was the percentage of patients who achieved euglycemia on day 3 of combination therapy. Patients were divided into euglycemic and dysglycemic cohorts based on the primary outcome. Univariate analysis on baseline characteristics, NPH dose, and steroid dose based on prednisone equivalent dose (PED) was conducted to identify differences between the cohorts. Safety analysis was conducted to detect differences between the two cohorts. Measurements and Main Results: Of 142 patients included in the primary analysis, 50 (35.2%) achieved euglycemia on day 3 of combination therapy. In univariate analysis, patients who achieved euglycemia had significantly higher median NPH dose standardized to steroid dose on day 1 (0.5 units/mg PED [25%–75% interquartile range (IQR) 0.4–0.8] vs 0.4 units/mg PED [0.2–0.8]; p = 0.046), lower median blood glucose prior to combination therapy on day 3 (111 mg/dl [96–160] vs 136 mg/dl [113–198]; p = 0.008), and lower median blood glucose 4 hours after administration of combination therapy on day 3 (147 mg/dl [116–197] vs 190 mg/dl [153–245]; p = 0.003) compared to patients who did not achieve euglycemia, respectively. Hypoglycemia and life‐threatening hypoglycemia occurred at similar rates between the two cohorts. Conclusions: Neutral protamine Hagedorn is a safe and efficacious option for acute care hospitalized patients experiencing steroid‐induced hyperglycemia. More aggressive dosing initiation of NPH based on steroid dose may allow for earlier achievement of euglycemia without a difference in hypoglycemia.
- Open Access
- 13 July 2013
- Published by BMJ in Sexually Transmitted Infections
- Vol. 89 (Suppl 1) , A267.1-A267
P3.376 Multidisciplinary Approach to Contain HIV-1 and Other STIs in China: Multipurpose Prevention Technologies
Background In China, the HIV prevalence continues to rise despite increasing efforts to contain the epidemic, and other sexually transmitted infections (STIs) are also on the increase. Furthermore, antibiotic-resistant STI pathogens are on the increase and many STIs facilitate the acquisition and/or transmission of HIV-1. Multipurpose prevention technologies (MPTs), including drugs, devices and vaccines that simultaneously prevent unintended pregnancies, HIV and other STIs, would provide effective approaches to meet these public health challenges. Methods The Initiative for MPTs developed Target Product Profiles (TPPs) to define key product attributes appropriate for those regions of the world hardest hit by unintended pregnancy, HIV, and other STIs. The TPP considered priority combinations of indications, mechanisms of action, dosing and administration, and formulation and delivery. Current and historic data from China were reviewed to determine which product attributes in an MPT would best meet the needs in China. Results Sexual transmission of HIV-1 has become the major route for new infection in China, and other STIs have increased more than 40 times from 1985. The increase in STI rates is associated with population mobility, and the geographic distribution of STIs overlaps with that of HIV, suggesting the possibility of co-infection. The rate of unintended pregnancy is low in China, given the “one child” policy. After analysing the current and historic data, we propose that MPTs specifically addressing HIV and STIs would best meet the public health challenges in China, and the preferred dosing form would be long-acting implant or IUD-based delivery. Conclusion The continuing rise in prevalence and rates of STIs, including HIV poses serious public health challenges to China, where sustained economic development has resulted in social transformation and unprecedented population mobility. MPTs that specifically target HIV and other STIs could provide an effective approach to meeting these public health challenges in China.
- 13 July 2013
- Published by BMJ in Sexually Transmitted Infections
- Vol. 89 (Suppl 1) , A267.1-A267
Open AccessP3.376 Multidisciplinary Approach to Contain HIV-1 and Other STIs in China: Multipurpose Prevention Technologies
Background In China, the HIV prevalence continues to rise despite increasing efforts to contain the epidemic, and other sexually transmitted infections (STIs) are also on the increase. Furthermore, antibiotic-resistant STI pathogens are on the increase and many STIs facilitate the acquisition and/or transmission of HIV-1. Multipurpose prevention technologies (MPTs), including drugs, devices and vaccines that simultaneously prevent unintended pregnancies, HIV and other STIs, would provide effective approaches to meet these public health challenges. Methods The Initiative for MPTs developed Target Product Profiles (TPPs) to define key product attributes appropriate for those regions of the world hardest hit by unintended pregnancy, HIV, and other STIs. The TPP considered priority combinations of indications, mechanisms of action, dosing and administration, and formulation and delivery. Current and historic data from China were reviewed to determine which product attributes in an MPT would best meet the needs in China. Results Sexual transmission of HIV-1 has become the major route for new infection in China, and other STIs have increased more than 40 times from 1985. The increase in STI rates is associated with population mobility, and the geographic distribution of STIs overlaps with that of HIV, suggesting the possibility of co-infection. The rate of unintended pregnancy is low in China, given the “one child” policy. After analysing the current and historic data, we propose that MPTs specifically addressing HIV and STIs would best meet the public health challenges in China, and the preferred dosing form would be long-acting implant or IUD-based delivery. Conclusion The continuing rise in prevalence and rates of STIs, including HIV poses serious public health challenges to China, where sustained economic development has resulted in social transformation and unprecedented population mobility. MPTs that specifically target HIV and other STIs could provide an effective approach to meeting these public health challenges in China.